ICER Reports - 4 Years of Cost/QALY Drug Evaluations in the USA...What Does the Future Hold?

May 16, 2018

Educational poster presented at ISPOR 16th Annual International Meeting, Baltimore, May 2018

Educational poster presented at ISPOR 16th Annual International Meeting, Baltimore, May 2018

Previous Article
Commercializing Regenerative Medicines in the US - What Lessons Can We Learn From Europe?
Commercializing Regenerative Medicines in the US - What Lessons Can We Learn From Europe?

Next Article
Mission Possible? Demonstrating Robust Cost-Effectiveness Without Any Comparative Phase III Data
Mission Possible? Demonstrating Robust Cost-Effectiveness Without Any Comparative Phase III Data

×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!